Cubic Pharmaceuticals: Announcement on the company’s products to be selected for centralized mass procurement of drugs organized by the country
Securities code: 003020 Securities abbreviation: Cubic Pharmaceuticals Announcement number: 2026-026
Hefei Cube Pharmaceutical Co., Ltd.
Announcement on the company’s products to be selected for centralized mass procurement of drugs organized by the state
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Recently, Hefei Cube Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Lifang Pharmaceutical") participated in the application for the centralized bulk purchase of drugs organized by the state (the 12th batch). According to the "Announcement of Proposed Selection Results for the 12th Batch of Nationally Organized Drug Centralized Procurement in Volume" issued by the Joint Procurement Office of State-Organized Drugs on July 31, 2026, some of the company's products are planned to be selected for this volume-based purchase. The relevant information is now announced as follows:
1. Basic information about the product to be selected
Serial number Drug name Specifications Indications
Symptomatic treatment of benign prostatic hyperplasia; high blood pressure 1 Doxazosin mesylate sustained-release tablets 4mg
treatment of pressure.
40mg,
2 Measartan Potassium Tablets are suitable for the treatment of essential hypertension in adults. 80mg
2. Impact on the company
The sales of the above products are as follows:
Accounting for the company's 2026
Account for the company's 2025 first quarter of 2026
Preface 2025 Sales First Quarter Operating Income
Drug name Annual operating revenue Sales revenue (without
Sales revenue/10,000 yuan (unaudited) ratio (audited)/10,000 yuan
Example
Dosha mesylate
1 10,340.95 6.66% 2,531.94 7.09%
Zosin extended-release tablets
Measartan Potassium
2 Approved for listing on May 19, 2026, but has not yet generated sales revenue.
film
This centralized procurement is the 12th batch of centralized bulk procurement of state-organized drugs organized by the Joint Procurement Office of State-Organized Drugs. The procurement cycle starts from the date of implementation of the winning results to December 31, 2029. The agreed purchase volume is based on the reported demand of medical institutions across the country and is comprehensively determined based on the selection rules and the volume ratio. During the procurement cycle, medical institutions will give priority to using this batch of drugs to purchase the selected drugs in batches and ensure that the agreed purchase amount is completed. If the company plans to sign a purchase contract for the selected product and implement it, it will help further expand the sales scale of related products, increase market share, enhance the company's brand influence, and have a positive impact on the company's future operating performance.
1/2
3. Risk warning
The results of the above-mentioned products to be selected need to be confirmed after no objection is announced, and subsequent matters such as the signing of the purchase contract for the products to be selected are still uncertain. The company will pay close attention to the progress of this matter and fulfill its information disclosure obligations in a timely manner. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Hefei Cube Pharmaceutical Co., Ltd.
August 3, 2026
2/2